Supporters so far
HOOFING IT! 2026 Total so far $10,685
Start Hoofing It! Registration is open join a team or start your own Register Now
2025 Results Together we raised $40,662 — thank you to all 150 donors & 11 teams Donate Today
Why It Matters Every step funds NET research, drug access, & patient support across Canada Learn More
Sponsor a Walker Can’t walk? Sponsor a team member — every dollar counts Sponsor Now
2026 Total So Far $10,685 raised of $60,000 — keep on HOOFING IT! Donate Now
Sponsor a Hoofing IT Walker
How Your Donation Helps
HOOFING IT 2026:
Donate Now
HOOFING IT! 2025:
Raised $40,662!

Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours

The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours.  Everolimus is a cancer medicine that [...]

By |2018-05-07T18:28:13-04:00April 16th, 2016|Treatment News|Comments Off on Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours
Read More

PRRT clinical trial at CHU de Québec

We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]

By |2018-05-07T18:28:14-04:00April 12th, 2016|Treatment News|Comments Off on PRRT clinical trial at CHU de Québec
Read More
Go to Top